Does nasal decongestion improve obstructive sleep apnea?
Summary Whether nasal congestion promotes obstructive sleep apnea is controversial. Therefore, we performed a randomized placebo‐controlled cross‐over trial on the effects of topical nasal decongestion in patients with obstructive sleep apnea syndrome (OSA) and nasal congestion. Twelve OSA patients...
Gespeichert in:
| Veröffentlicht in: | Journal of sleep research 2008-12, Vol.17 (4), p.444-449 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 449 |
|---|---|
| container_issue | 4 |
| container_start_page | 444 |
| container_title | Journal of sleep research |
| container_volume | 17 |
| creator | CLARENBACH, CHRISTIAN F. KOHLER, MALCOLM SENN, OLIVER THURNHEER, ROBERT BLOCH, KONRAD E. |
| description | Summary
Whether nasal congestion promotes obstructive sleep apnea is controversial. Therefore, we performed a randomized placebo‐controlled cross‐over trial on the effects of topical nasal decongestion in patients with obstructive sleep apnea syndrome (OSA) and nasal congestion. Twelve OSA patients with chronic nasal congestion (mean ± SD age 49.1 ± 11.1 years, apnea/hypopnea index 32.6 ± 24.5/h) were treated with nasal xylometazoline or placebo for 1 week each. At the end of treatment periods, polysomnography including monitoring of nasal conductance by an unobtrusive technique, vigilance by the OSLER test, and symptom scores were assessed. Data from xylometazoline and placebo treatments were compared. Mean nocturnal nasal conductance on xylometazoline was significantly higher than on placebo (8.6 ± 5.3 versus 6.3 ± 5.8 mL s−1Pa−1, P |
| doi_str_mv | 10.1111/j.1365-2869.2008.00667.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69906667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69906667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3977-b794428c71b151f5b2dd022de48970c9561cb0893461d5cd1484f5b26ccb8d713</originalsourceid><addsrcrecordid>eNqNkNtKxDAQhoMo7rr6CtIr71pn0jYHEETWMwuCh-vQJlnp0pPNVnff3tQuemtuJpBvJv98hAQIEfpzvoowZmlIBZMRBRARAGM82uyR6e_DPpmCZDREhHRCjpxbASBPY3lIJig4QkJhSsR1Y11QZy4rA2N1U79bty6aOiiqtms-bdDkbt31el34uyutbYOsrW12eUwOllnp7Mmuzsjb7c3r_D5cPN09zK8WoY4l52HOZZJQoTnmmOIyzakxQKmxiZActEwZ6hyEjBOGJtUGE5EMFNM6F4ZjPCNn41wf56P34VRVOG3LMqtt0zvFpPS7M-5BMYK6a5zr7FK1XVFl3VYhqMGaWqlBjhrkqMGa-rGmNr71dPdHn1fW_DXuNHngYgS-itJu_z1YPb48D9G-AZcYehs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69906667</pqid></control><display><type>article</type><title>Does nasal decongestion improve obstructive sleep apnea?</title><source>MEDLINE</source><source>Wiley Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>CLARENBACH, CHRISTIAN F. ; KOHLER, MALCOLM ; SENN, OLIVER ; THURNHEER, ROBERT ; BLOCH, KONRAD E.</creator><creatorcontrib>CLARENBACH, CHRISTIAN F. ; KOHLER, MALCOLM ; SENN, OLIVER ; THURNHEER, ROBERT ; BLOCH, KONRAD E.</creatorcontrib><description>Summary
Whether nasal congestion promotes obstructive sleep apnea is controversial. Therefore, we performed a randomized placebo‐controlled cross‐over trial on the effects of topical nasal decongestion in patients with obstructive sleep apnea syndrome (OSA) and nasal congestion. Twelve OSA patients with chronic nasal congestion (mean ± SD age 49.1 ± 11.1 years, apnea/hypopnea index 32.6 ± 24.5/h) were treated with nasal xylometazoline or placebo for 1 week each. At the end of treatment periods, polysomnography including monitoring of nasal conductance by an unobtrusive technique, vigilance by the OSLER test, and symptom scores were assessed. Data from xylometazoline and placebo treatments were compared. Mean nocturnal nasal conductance on xylometazoline was significantly higher than on placebo (8.6 ± 5.3 versus 6.3 ± 5.8 mL s−1Pa−1, P < 0.05) but the apnea/hypopnea index was similar (29.3 ± 32.5/h versus 33.2 ± 32.8/h, P = NS). However, 30–210 min after application of xylometazoline, at the time of the maximal pharmacologic effect, the apnea/hypopnea index was slightly reduced (27.3 ± 30.5/h versus 33.2 ± 33.9/h, P < 0.05). Xylometazoline did not alter sleep quality, sleep resistance time (33.6 ± 8.8 versus 33.4 ± 10.1 min, P = NS) and subjective sleepiness (Epworth score 10.5 ± 3.8 versus 11.8 ± 4.4, P = NS). The reduced apnea/hypopnea index during maximal nasal decongestion by xylometazoline suggests a pathophysiologic link but the efficacy of nasal decongestion was not sufficient to provide a clinically substantial improvement of OSA. ClinicalTrials.gov Identifier is NTC006030474.</description><identifier>ISSN: 0962-1105</identifier><identifier>EISSN: 1365-2869</identifier><identifier>DOI: 10.1111/j.1365-2869.2008.00667.x</identifier><identifier>PMID: 18710420</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Chronic Disease ; Cross-Over Studies ; Double-Blind Method ; Female ; Humans ; Imidazoles - therapeutic use ; Male ; Middle Aged ; Nasal Decongestants - therapeutic use ; nasal resistance ; obstructive sleep apnea ; rhinitis ; Rhinitis - drug therapy ; Sleep Apnea, Obstructive - drug therapy ; sleep quality</subject><ispartof>Journal of sleep research, 2008-12, Vol.17 (4), p.444-449</ispartof><rights>2008 European Sleep Research Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3977-b794428c71b151f5b2dd022de48970c9561cb0893461d5cd1484f5b26ccb8d713</citedby><cites>FETCH-LOGICAL-c3977-b794428c71b151f5b2dd022de48970c9561cb0893461d5cd1484f5b26ccb8d713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2869.2008.00667.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2869.2008.00667.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18710420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CLARENBACH, CHRISTIAN F.</creatorcontrib><creatorcontrib>KOHLER, MALCOLM</creatorcontrib><creatorcontrib>SENN, OLIVER</creatorcontrib><creatorcontrib>THURNHEER, ROBERT</creatorcontrib><creatorcontrib>BLOCH, KONRAD E.</creatorcontrib><title>Does nasal decongestion improve obstructive sleep apnea?</title><title>Journal of sleep research</title><addtitle>J Sleep Res</addtitle><description>Summary
Whether nasal congestion promotes obstructive sleep apnea is controversial. Therefore, we performed a randomized placebo‐controlled cross‐over trial on the effects of topical nasal decongestion in patients with obstructive sleep apnea syndrome (OSA) and nasal congestion. Twelve OSA patients with chronic nasal congestion (mean ± SD age 49.1 ± 11.1 years, apnea/hypopnea index 32.6 ± 24.5/h) were treated with nasal xylometazoline or placebo for 1 week each. At the end of treatment periods, polysomnography including monitoring of nasal conductance by an unobtrusive technique, vigilance by the OSLER test, and symptom scores were assessed. Data from xylometazoline and placebo treatments were compared. Mean nocturnal nasal conductance on xylometazoline was significantly higher than on placebo (8.6 ± 5.3 versus 6.3 ± 5.8 mL s−1Pa−1, P < 0.05) but the apnea/hypopnea index was similar (29.3 ± 32.5/h versus 33.2 ± 32.8/h, P = NS). However, 30–210 min after application of xylometazoline, at the time of the maximal pharmacologic effect, the apnea/hypopnea index was slightly reduced (27.3 ± 30.5/h versus 33.2 ± 33.9/h, P < 0.05). Xylometazoline did not alter sleep quality, sleep resistance time (33.6 ± 8.8 versus 33.4 ± 10.1 min, P = NS) and subjective sleepiness (Epworth score 10.5 ± 3.8 versus 11.8 ± 4.4, P = NS). The reduced apnea/hypopnea index during maximal nasal decongestion by xylometazoline suggests a pathophysiologic link but the efficacy of nasal decongestion was not sufficient to provide a clinically substantial improvement of OSA. ClinicalTrials.gov Identifier is NTC006030474.</description><subject>Chronic Disease</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Imidazoles - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nasal Decongestants - therapeutic use</subject><subject>nasal resistance</subject><subject>obstructive sleep apnea</subject><subject>rhinitis</subject><subject>Rhinitis - drug therapy</subject><subject>Sleep Apnea, Obstructive - drug therapy</subject><subject>sleep quality</subject><issn>0962-1105</issn><issn>1365-2869</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkNtKxDAQhoMo7rr6CtIr71pn0jYHEETWMwuCh-vQJlnp0pPNVnff3tQuemtuJpBvJv98hAQIEfpzvoowZmlIBZMRBRARAGM82uyR6e_DPpmCZDREhHRCjpxbASBPY3lIJig4QkJhSsR1Y11QZy4rA2N1U79bty6aOiiqtms-bdDkbt31el34uyutbYOsrW12eUwOllnp7Mmuzsjb7c3r_D5cPN09zK8WoY4l52HOZZJQoTnmmOIyzakxQKmxiZActEwZ6hyEjBOGJtUGE5EMFNM6F4ZjPCNn41wf56P34VRVOG3LMqtt0zvFpPS7M-5BMYK6a5zr7FK1XVFl3VYhqMGaWqlBjhrkqMGa-rGmNr71dPdHn1fW_DXuNHngYgS-itJu_z1YPb48D9G-AZcYehs</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>CLARENBACH, CHRISTIAN F.</creator><creator>KOHLER, MALCOLM</creator><creator>SENN, OLIVER</creator><creator>THURNHEER, ROBERT</creator><creator>BLOCH, KONRAD E.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200812</creationdate><title>Does nasal decongestion improve obstructive sleep apnea?</title><author>CLARENBACH, CHRISTIAN F. ; KOHLER, MALCOLM ; SENN, OLIVER ; THURNHEER, ROBERT ; BLOCH, KONRAD E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3977-b794428c71b151f5b2dd022de48970c9561cb0893461d5cd1484f5b26ccb8d713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Chronic Disease</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Imidazoles - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nasal Decongestants - therapeutic use</topic><topic>nasal resistance</topic><topic>obstructive sleep apnea</topic><topic>rhinitis</topic><topic>Rhinitis - drug therapy</topic><topic>Sleep Apnea, Obstructive - drug therapy</topic><topic>sleep quality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CLARENBACH, CHRISTIAN F.</creatorcontrib><creatorcontrib>KOHLER, MALCOLM</creatorcontrib><creatorcontrib>SENN, OLIVER</creatorcontrib><creatorcontrib>THURNHEER, ROBERT</creatorcontrib><creatorcontrib>BLOCH, KONRAD E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of sleep research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CLARENBACH, CHRISTIAN F.</au><au>KOHLER, MALCOLM</au><au>SENN, OLIVER</au><au>THURNHEER, ROBERT</au><au>BLOCH, KONRAD E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does nasal decongestion improve obstructive sleep apnea?</atitle><jtitle>Journal of sleep research</jtitle><addtitle>J Sleep Res</addtitle><date>2008-12</date><risdate>2008</risdate><volume>17</volume><issue>4</issue><spage>444</spage><epage>449</epage><pages>444-449</pages><issn>0962-1105</issn><eissn>1365-2869</eissn><abstract>Summary
Whether nasal congestion promotes obstructive sleep apnea is controversial. Therefore, we performed a randomized placebo‐controlled cross‐over trial on the effects of topical nasal decongestion in patients with obstructive sleep apnea syndrome (OSA) and nasal congestion. Twelve OSA patients with chronic nasal congestion (mean ± SD age 49.1 ± 11.1 years, apnea/hypopnea index 32.6 ± 24.5/h) were treated with nasal xylometazoline or placebo for 1 week each. At the end of treatment periods, polysomnography including monitoring of nasal conductance by an unobtrusive technique, vigilance by the OSLER test, and symptom scores were assessed. Data from xylometazoline and placebo treatments were compared. Mean nocturnal nasal conductance on xylometazoline was significantly higher than on placebo (8.6 ± 5.3 versus 6.3 ± 5.8 mL s−1Pa−1, P < 0.05) but the apnea/hypopnea index was similar (29.3 ± 32.5/h versus 33.2 ± 32.8/h, P = NS). However, 30–210 min after application of xylometazoline, at the time of the maximal pharmacologic effect, the apnea/hypopnea index was slightly reduced (27.3 ± 30.5/h versus 33.2 ± 33.9/h, P < 0.05). Xylometazoline did not alter sleep quality, sleep resistance time (33.6 ± 8.8 versus 33.4 ± 10.1 min, P = NS) and subjective sleepiness (Epworth score 10.5 ± 3.8 versus 11.8 ± 4.4, P = NS). The reduced apnea/hypopnea index during maximal nasal decongestion by xylometazoline suggests a pathophysiologic link but the efficacy of nasal decongestion was not sufficient to provide a clinically substantial improvement of OSA. ClinicalTrials.gov Identifier is NTC006030474.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18710420</pmid><doi>10.1111/j.1365-2869.2008.00667.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0962-1105 |
| ispartof | Journal of sleep research, 2008-12, Vol.17 (4), p.444-449 |
| issn | 0962-1105 1365-2869 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69906667 |
| source | MEDLINE; Wiley Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Chronic Disease Cross-Over Studies Double-Blind Method Female Humans Imidazoles - therapeutic use Male Middle Aged Nasal Decongestants - therapeutic use nasal resistance obstructive sleep apnea rhinitis Rhinitis - drug therapy Sleep Apnea, Obstructive - drug therapy sleep quality |
| title | Does nasal decongestion improve obstructive sleep apnea? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T05%3A12%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20nasal%20decongestion%20improve%20obstructive%20sleep%20apnea?&rft.jtitle=Journal%20of%20sleep%20research&rft.au=CLARENBACH,%20CHRISTIAN%20F.&rft.date=2008-12&rft.volume=17&rft.issue=4&rft.spage=444&rft.epage=449&rft.pages=444-449&rft.issn=0962-1105&rft.eissn=1365-2869&rft_id=info:doi/10.1111/j.1365-2869.2008.00667.x&rft_dat=%3Cproquest_cross%3E69906667%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69906667&rft_id=info:pmid/18710420&rfr_iscdi=true |